Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer.

Health technology assessment (Winchester, England)

Volumn 13 Suppl 2, Issue , 2009, Pages 69-74

  Bond, M ^a   Hoyle, M ^b   Moxham, T ^b   Napier, M ^b   Anderson, R ^b  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; SUNITINIB;

COST BENEFIT ANALYSIS; DRUG INDUSTRY; ECONOMICS; GASTROINTESTINAL STROMAL TUMOR; HUMAN; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG INDUSTRY; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; PYRROLES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

MLCS; MLOWN;

EID: 84886943002     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl2/10     Document Type: Review

References (18)